Who We Are

Overview

Elgia Therapeutics is a venture-backed biopharmaceutical company pioneering novel molecular approaches for the treatment of metabolic, inflammatory, and fibrotic diseases. The members of the Elgia leadership team are world-renowned scientists with synergistic expertise in innate immunity, metabolic syndromes, inflammatory processes, and drug discovery.

Overview

Elgia Therapeutics is a venture-backed biopharmaceutical company pioneering novel molecular approaches for the treatment of metabolic, inflammatory, and fibrotic diseases. The members of the Elgia leadership team are world-renowned scientists with synergistic expertise in innate immunity, metabolic syndromes, inflammatory processes, and drug discovery.

Elgia Leadership Team:
Disease and Drug Discovery Expertise

All members of the Elgia leadership team have start-up and/or biopharmaceutical experience and have played leadership roles in the delivery of multiple therapeutics. Elgia was founded in April 2020 by research scientists Alan Saltiel, Ariel Feldstein, Michael Karin, Michelle Arkin, and Adam Renslo, who are leaders in the biology of innate immunity, inflammation, and wound healing, experts in the biochemistry of key enzymes that control inflammation and cell demise, and authorities in disease pharmacology. Stacie Canan, a 28-year biopharma veteran, joined the leadership team in August 2020.

Alan Saltiel, Ph.D.
Founder and CEO

Ariel Feldstein, M.D.
Founder and CSO

Michael Karin, Ph.D.
Founder

Michelle Arkin, Ph.D.
Founder

Adam Renslo, Ph.D.
Founder

Stacie Canan, Ph.D.
COO and VP Drug Discovery